Successful monotherapy with autologous formalin-fixed tumor vaccine for
a stage IV uterine cancer patient rejecting rational chemotherapy and
immune-checkpoint-inhibitor treatment
Abstract
A patient with stage IV uterine cancer displaying circulating tumor
cells and high microsatellite instability who had rejected standard
chemotherapy and immune-check-point inhibitor treatment received
monotherapy with autologous formalin-fixed tumor vaccine (AFTV). The
treatment resulted in shrinkage of multiple lung metastases, suggesting
that AFTV will be an attractive treatment option.